Kalaris Therapeutics (KLRS) Receivables - Other (2019 - 2024)
Kalaris Therapeutics (KLRS) posted quarterly Receivables - Other of $53000.0 for Q3 2024, down 77.35% year-over-year from $234000.0 in Q4 2023, and down 44.79% quarter-over-quarter from $96000.0 in Q2 2024.
Kalaris Therapeutics (KLRS) Receivables - Other (2019 - 2024) Analysis & Trends
Kalaris Therapeutics' Receivables - Other history runs 6 years deep, the most recent figure standing at $53000.0 for Q3 2024.
- In Q3 2024, Receivables - Other fell 77.35% year-over-year to $53000.0; the TTM figure through Sep 2024 stood at $53000.0 (down 77.35% YoY), while the FY2023 annual figure was $206000.0, up 31.21% from the prior year.
- Receivables - Other for Q3 2024 stood at $53000.0, down from $96000.0 in the prior quarter.
- The five-year high for Receivables - Other was $469000.0 in Q1 2021, with the low at $50000.0 in Q4 2021.
- The 5-year median for Receivables - Other is $176500.0 (2022), against an average of $211722.2.
- Peak annual rise in Receivables - Other reached 605.17% in 2021, while the deepest fall reached 88.89% in 2021.
- Kalaris Therapeutics' Receivables - Other stood at $450000.0 in 2020, then plunged by 88.89% to $50000.0 in 2021, then surged by 214.0% to $157000.0 in 2022, then jumped by 31.21% to $206000.0 in 2023, then slumped by 74.27% to $53000.0 in 2024.
- Business Quant data shows KLRS's Receivables - Other at $53000.0 in Q3 2024, $96000.0 in Q2 2024, and $181000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | Kalaris Therapeutics | 97.57 Mn | 97.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 53,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 106,000.00 |
| Jun 30, 2023 | 106,000.00 |
| Mar 31, 2023 | 244,000.00 |
| Mar 31, 2023 | 244,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Jun 30, 2022 | 91,000.00 |
| Jun 30, 2022 | 91,000.00 |